



## Clinical trial results:

### **GEMCITABINE COMBINED WITH THE mTOR INHIBITOR TEMSIROLIMUS (CCI-779) IN PATIENTS WITH INOPERABLE OR METASTATIC PANCREATIC CANCER**

#### **Summary**

EudraCT number	2008-002791-10
Trial protocol	GR
Global end of trial date	27 May 2015

#### **Results information**

Result version number	v1 (current)
This version publication date	19 April 2019
First version publication date	19 April 2019

#### **Trial information**

##### **Trial identification**

Sponsor protocol code	HE 3/07
-----------------------	---------

##### **Additional study identifiers**

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	-
WHO universal trial number (UTN)	-
Other trial identifiers	ANZCTR: ACTRN12611000643976

Notes:

##### **Sponsors**

Sponsor organisation name	Hellenic Cooperative Oncology Group
Sponsor organisation address	Hatzikonstandi 18, Athens, Greece, 11524
Public contact	Hellenic Cooperative Oncology Group, Hellenic Cooperative Oncology Group, hecogoff@otenet.gr
Scientific contact	Hellenic Cooperative Oncology Group, Hellenic Cooperative Oncology Group, hecogoff@otenet.gr

Notes:

##### **Paediatric regulatory details**

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	05 January 2018
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	27 May 2015
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

The primary objective of this study is:

1. Determine the maximum tolerated dose and recommended phase II dose of temsirolimus and gemcitabine in patients with pancreatic cancer.
2. To estimate the progression free survival in patients treated with the temsirolimus+gemcitabine combination.

Protection of trial subjects:

The study was in compliance with the ethical principles derived from the Declaration of Helsinki and the International Conference on Harmonization (ICH) Good Clinical Practice (GCP) guidelines. All the local regulatory requirements pertinent to safety of trial subjects were also followed during the conduct of the trial. A copy of the IEC/IRB approval was received by the sponsor before recruitment of subjects into the study and all subjects provided written informed consent before undergoing any study-related procedures.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	19 May 2009
Long term follow-up planned	Yes
Long term follow-up rationale	Efficacy
Long term follow-up duration	5 Years
Independent data monitoring committee (IDMC) involvement?	No

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Greece: 85
Worldwide total number of subjects	85
EEA total number of subjects	85

Notes:

### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0

Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	52
From 65 to 84 years	33
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details:

Participants were enrolled in the study from 19 May 2009 until 8 October 2014 from 8 sites in Greece.

### Pre-assignment

Screening details:

Patients signed the informed consent form and were screened for eligibility before entering the study

### Period 1

Period 1 title	overall trial (overall period)
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

### Arms

Are arms mutually exclusive?	Yes
------------------------------	-----

<b>Arm title</b>	Phase I
------------------	---------

Arm description:

Chemotherapy naive patients with inoperable or metastatic pancreatic carcinoma were enrolled to the study in 6 dose levels in order to determine the maximum tolerated dose and recommended Phase II dose of temsirolimus and gemcitabine.

Arm type	Experimental
Investigational medicinal product name	TORISEL
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate and solvent for solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Level 1: 10mg  
Level 2: 15mg  
Level 3: 20mg  
Level 4: 25mg  
Level 5: 20mg  
Level 6: 25mg

<b>Arm title</b>	Phase II
------------------	----------

Arm description:

Dose level 6 of gemcitabine 1000mg/m<sup>2</sup> and temsirolimus 25mg was the recommended dose for the Phase II study in patients with inoperable or metastatic pancreatic cancer

Arm type	Experimental
Investigational medicinal product name	TORISEL
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate and solvent for solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Torisel 25mg was the recommended dose for the Phase II study

<b>Number of subjects in period 1</b>	Phase I	Phase II
Started	30	55
Completed	3	4
Not completed	27	51
Clinical progression	2	-
Adverse event, serious fatal	-	4
Consent withdrawn by subject	-	5
Physician decision	-	1
Disease progression	16	31
Adverse event, non-fatal	3	8
Non-starter	1	-
Death	1	2
More than one month elapsed	1	-
Performance status lower than 50	1	-
Protocol deviation	2	-

## Baseline characteristics

### Reporting groups

Reporting group title	Phase I
-----------------------	---------

Reporting group description:

Chemotherapy naive patients with inoperable or metastatic pancreatic carcinoma were enrolled to the study in 6 dose levels in order to determine the maximum tolerated dose and recommended Phase II dose of temsirolimus and gemcitabine.

Reporting group title	Phase II
-----------------------	----------

Reporting group description:

Dose level 6 of gemcitabine 1000mg/m<sup>2</sup> and temsirolimus 25mg was the recommended dose for the Phase II study in patients with inoperable or metastatic pancreatic cancer

Reporting group values	Phase I	Phase II	Total
Number of subjects	30	55	85
Age categorical			
Units: Subjects			
Adults (18-64 years)	19	33	52
From 65-84 years	11	22	33
85 years and over	0	0	0
Age continuous			
Units: years			
median	62.4	62.1	
full range (min-max)	42.2 to 81.3	38.7 to 77.8	-
Gender categorical			
Units: Subjects			
Female	14	23	37
Male	16	32	48

## End points

### End points reporting groups

Reporting group title	Phase I
Reporting group description: Chemotherapy naive patients with inoperable or metastatic pancreatic carcinoma were enrolled to the study in 6 dose levels in order to determine the maximum tolerated dose and recommended Phase II dose of temsirolimus and gemcitabine.	
Reporting group title	Phase II
Reporting group description: Dose level 6 of gemcitabine 1000mg/m2 and temsirolimus 25mg was the recommended dose for the Phase II study in patients with inoperable or metastatic pancreatic cancer	

### Primary: Maximum Tolerated Dose of Gemcitabine (G) and Temsirolimus (T)

End point title	Maximum Tolerated Dose of Gemcitabine (G) and Temsirolimus (T) <sup>[1][2]</sup>
End point description: In the Phase I part of the study, 30 patients were enrolled, at least 3 subjects at each dose level in order to determine the recommended dose for the Phase II part of the study.	
End point type	Primary
End point timeframe: From study initiation until the determination of the maximum tolerated dose.	
Notes:	

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Gemcitabine doses per dose level are described for patients enrolled in the Phase I part of the study.

[2] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The determination of the maximum tolerated dose of Gemcitabine and Temsirolimus was the primary endpoint of the Phase I part of the study. The number of patients evaluable for DLT per dose level is described for patients enrolled in the Phase I part of the study.

End point values	Phase I			
Subject group type	Reporting group			
Number of subjects analysed	30 <sup>[3]</sup>			
Units: number of patients evaluable for DLT				
Dose Level 1 G (800mg/m2),T (10 mg)	7			
Dose Level 2 G (800mg/m2), T(15mg)	3			
Dose Level 3 G(800mg/m2),T(20 mg)	6			
Dose Level 4 G(800mg/m2),T(25 mg)	3			
Dose Level 5 G (1000 mg/m2),T(20 mg)	3			
Dose Level 6 G(1000 mg/m2),T(25 mg)	3			

Notes:

[3] - In the first dose level one patient did not start treatment and one was ineligible.

### Statistical analyses

No statistical analyses for this end point

## Primary: 6-month Progression Free Survival

End point title	6-month Progression Free Survival <sup>[4][5]</sup>
-----------------	---

End point description:

Progression- Free Survival (PFS) was calculated from the date of study entry to the date of first documented progression, death or last contact.

End point type	Primary
----------------	---------

End point timeframe:

tumor assessments were performed in cycles 2,4 and 7

Notes:

[4] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Since this was a single arm Phase I/II trial and all patients were treated with Gemcitabine and Temsirolimus, no comparisons between different treatment arms were performed. The percentage of patients surviving 6 months since study entry has been provided for the patients included in the Phase II part of the study.

[5] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The 6-month progression free survival rate was the primary endpoint of the Phase II part of the study. The percentage of Phase II patients surviving 6 months since study entry is described.

End point values	Phase II			
Subject group type	Reporting group			
Number of subjects analysed	55			
Units: percentage of surviving patients				
number (not applicable)	30.9			

<b>Attachments (see zip file)</b>	Kaplan-Meier for PFS/KM_PFS_29112018.tiff
-----------------------------------	---

## Statistical analyses

No statistical analyses for this end point

## Secondary: Quality of life benefits

End point title	Quality of life benefits <sup>[6]</sup>
-----------------	---

End point description:

Quality of life was assessed using the EUROQOL 5D Questionnaire. The descriptive system consists of 5 dimensions including mobility, self-care, usual activities, pain/discomfort and anxiety/depression. The single summary EQ-5D Index was calculated using the European value set.

End point type	Secondary
----------------	-----------

End point timeframe:

Quality of life questionnaires were completed on screening-baseline, on cycles 4, 7 and 6 months after completion of treatment

Notes:

[6] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The Quality of Life assessment was a secondary endpoint of the Phase II part of the trial and therefore measures of central tendency and dispersion of the calculated EQ-5D Index are provided for Phase II patients that completed the EQ-5D questionnaire at baseline and at the last treatment cycle.

End point values	Phase II			
Subject group type	Reporting group			
Number of subjects analysed	55 <sup>[7]</sup>			
Units: EQ-5D Index				
arithmetic mean (standard deviation)				
Baseline	0.67 (± 0.21)			
Last treatment cycle	0.65 (± 0.26)			

Notes:

[7] - 51 patients (92.7%) completed the EQ-5D questionnaire at baseline and 30 at the last treatment cycle

<b>Attachments (see zip file)</b>	Histogram of the difference of EQ-5D Index/EQ5D_Difference.
-----------------------------------	---

## Statistical analyses

No statistical analyses for this end point

## Secondary: Overall Survival

End point title	Overall Survival <sup>[8]</sup>
-----------------	---------------------------------

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

overall survival was measured from the date of patient's study entry to the date of death or last contact.

Notes:

[8] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Overall Survival was a secondary endpoint of the Phase II part of the trial. Therefore, the median overall survival (in months) with the corresponding 95% confidence intervals are provided for the 55 patients included in the Phase II part of the study.

End point values	Phase II			
Subject group type	Reporting group			
Number of subjects analysed	55			
Units: months				
median (confidence interval 95%)	4.95 (3.54 to 6.85)			

<b>Attachments (see zip file)</b>	Kaplan-Meier for Overall Survival/KM_OS_29112018.tiff
-----------------------------------	---

## Statistical analyses

No statistical analyses for this end point

## Secondary: Adverse events and serious adverse events of temsirolimus combination and gemcitabine

End point title	Adverse events and serious adverse events of temsirolimus combination and gemcitabine
-----------------	---

End point description:

Assessment of the nature, incidence and severity of adverse events and serious adverse events of the

combination of temsirolimus and gemcitabine.

End point type	Secondary
----------------	-----------

End point timeframe:

Adverse events and serious adverse events of all participants were recorded and assessed upon signature of the informed consent until 30 days after the last administration of study treatment.

End point values	Phase I	Phase II		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	29 <sup>[9]</sup>	55		
Units: number of patients				
Any Adverse Event	29	53		
Adverse Events grade $\geq 3$	28	47		
Adverse Events grade $\geq 4$	8	25		
Fatal Adverse Events	1	5		
Serious Adverse Events	14	31		

Notes:

[9] - One patient never started treatment and was therefore excluded from the safety population.

## Statistical analyses

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Upon signature of the informed consent form until 30 days after the last administration of the investigational medicinal product.

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	9.1
--------------------	-----

### Reporting groups

Reporting group title	Phase I
-----------------------	---------

Reporting group description:

chemotherapy naive patients with inoperable or metastatic pancreatic carcinoma were enrolled to the study in 6 dose levels in order to determine the maximum tolerated dose and recommended Phase II dose of temsirolimus and gemcitabine

Reporting group title	Phase II
-----------------------	----------

Reporting group description:

dose level 6 of gemcitabine 1000mg/m<sup>2</sup> and temsirolimus 25mg was the recommended dose for the Phase II study in patients with inoperable or metastatic pancreatic cancer

Serious adverse events	Phase I	Phase II	
Total subjects affected by serious adverse events			
subjects affected / exposed	14 / 29 (48.28%)	31 / 55 (56.36%)	
number of deaths (all causes)	1	54	
number of deaths resulting from adverse events	1	5	
Investigations			
bilirubin total increased			
subjects affected / exposed	2 / 29 (6.90%)	0 / 55 (0.00%)	
occurrences causally related to treatment / all	1 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thrombocytopenia			
subjects affected / exposed	1 / 29 (3.45%)	0 / 55 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neutropenia			
subjects affected / exposed	1 / 29 (3.45%)	0 / 55 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood bilirubin increased			

subjects affected / exposed	0 / 29 (0.00%)	1 / 55 (1.82%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Vascular disorders</b>			
Pulmonary embolism			
subjects affected / exposed	1 / 29 (3.45%)	6 / 55 (10.91%)	
occurrences causally related to treatment / all	1 / 1	6 / 6	
deaths causally related to treatment / all	0 / 0	1 / 1	
Thrombosis			
subjects affected / exposed	0 / 29 (0.00%)	1 / 55 (1.82%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
hematoma			
subjects affected / exposed	0 / 29 (0.00%)	1 / 55 (1.82%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Deep vein thrombosis			
subjects affected / exposed	0 / 29 (0.00%)	1 / 55 (1.82%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Cardiac disorders</b>			
Myocardial infarction			
subjects affected / exposed	1 / 29 (3.45%)	0 / 55 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	1 / 1	0 / 0	
Chest pain			
subjects affected / exposed	0 / 29 (0.00%)	1 / 55 (1.82%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Nervous system disorders</b>			
Ischaemic stroke			
subjects affected / exposed	0 / 29 (0.00%)	1 / 55 (1.82%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

General disorders and administration site conditions			
fever			
subjects affected / exposed	1 / 29 (3.45%)	5 / 55 (9.09%)	
occurrences causally related to treatment / all	1 / 1	4 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
tumour progression	Additional description: clinical tumour progression		
alternative dictionary used: MedDRA 21.1			
subjects affected / exposed	1 / 29 (3.45%)	0 / 55 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
multiple organ failure			
subjects affected / exposed	1 / 29 (3.45%)	0 / 55 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	1 / 1	0 / 0	
fatigue			
subjects affected / exposed	1 / 29 (3.45%)	1 / 55 (1.82%)	
occurrences causally related to treatment / all	1 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sudden death			
subjects affected / exposed	0 / 29 (0.00%)	1 / 55 (1.82%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	1 / 29 (3.45%)	0 / 55 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal disorders			
Nausea			
subjects affected / exposed	1 / 29 (3.45%)	1 / 55 (1.82%)	
occurrences causally related to treatment / all	1 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vomiting			

subjects affected / exposed	2 / 29 (6.90%)	6 / 55 (10.91%)	
occurrences causally related to treatment / all	2 / 2	4 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
hemorrhage upper gastrointestinal NOS			
subjects affected / exposed	1 / 29 (3.45%)	0 / 55 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Constipation			
subjects affected / exposed	1 / 29 (3.45%)	0 / 55 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ileus			
subjects affected / exposed	1 / 29 (3.45%)	1 / 55 (1.82%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
stent obstruction			
subjects affected / exposed	1 / 29 (3.45%)	0 / 55 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatobiliary disorders			
obstruction of the bile duct			
subjects affected / exposed	1 / 29 (3.45%)	0 / 55 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
obstruction of the biliary tract			
subjects affected / exposed	0 / 29 (0.00%)	1 / 55 (1.82%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory, thoracic and mediastinal disorders			
Pneumonitis			
subjects affected / exposed	0 / 29 (0.00%)	1 / 55 (1.82%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Dyspnoea			
subjects affected / exposed	0 / 29 (0.00%)	1 / 55 (1.82%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
respiratory infection			
subjects affected / exposed	0 / 29 (0.00%)	1 / 55 (1.82%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Psychiatric disorders			
Depression			
subjects affected / exposed	0 / 29 (0.00%)	1 / 55 (1.82%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal and connective tissue disorders			
Bone pain			
subjects affected / exposed	1 / 29 (3.45%)	0 / 55 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations			
Pneumonia	Additional description: pneumonia infection which was caused due to Klebsiella		
subjects affected / exposed	1 / 29 (3.45%)	0 / 55 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	1 / 1	0 / 0	
Sepsis			
subjects affected / exposed	1 / 29 (3.45%)	0 / 55 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	1 / 1	0 / 0	
Infection			
subjects affected / exposed	2 / 29 (6.90%)	0 / 55 (0.00%)	
occurrences causally related to treatment / all	2 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
infection bladder			

subjects affected / exposed	1 / 29 (3.45%)	0 / 55 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lung infection			
subjects affected / exposed	0 / 29 (0.00%)	4 / 55 (7.27%)	
occurrences causally related to treatment / all	0 / 0	4 / 4	
deaths causally related to treatment / all	0 / 0	1 / 1	
Bacteraemia			
subjects affected / exposed	0 / 29 (0.00%)	1 / 55 (1.82%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary tract infection			
subjects affected / exposed	0 / 29 (0.00%)	1 / 55 (1.82%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Febrile neutropenia			
subjects affected / exposed	0 / 29 (0.00%)	3 / 55 (5.45%)	
occurrences causally related to treatment / all	0 / 0	3 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
infection with grade 3 lymphopenia alternative dictionary used: CTCAE 3			
subjects affected / exposed	0 / 29 (0.00%)	1 / 55 (1.82%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Opportunistic infection			
subjects affected / exposed	0 / 29 (0.00%)	1 / 55 (1.82%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	1 / 1	
stent infection			
subjects affected / exposed	0 / 29 (0.00%)	1 / 55 (1.82%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 0 %

<b>Non-serious adverse events</b>	Phase I	Phase II	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	28 / 29 (96.55%)	52 / 55 (94.55%)	
Vascular disorders			
Hypotension			
subjects affected / exposed	1 / 29 (3.45%)	1 / 55 (1.82%)	
occurrences (all)	2	1	
Flushing			
subjects affected / exposed	0 / 29 (0.00%)	1 / 55 (1.82%)	
occurrences (all)	0	1	
Phlebitis			
subjects affected / exposed	1 / 29 (3.45%)	0 / 55 (0.00%)	
occurrences (all)	1	0	
Embolism			
subjects affected / exposed	1 / 29 (3.45%)	3 / 55 (5.45%)	
occurrences (all)	1	3	
General disorders and administration site conditions			
Fatigue			
subjects affected / exposed	15 / 29 (51.72%)	19 / 55 (34.55%)	
occurrences (all)	25	21	
fever			
subjects affected / exposed	8 / 29 (27.59%)	12 / 55 (21.82%)	
occurrences (all)	11	28	
Chills			
subjects affected / exposed	2 / 29 (6.90%)	1 / 55 (1.82%)	
occurrences (all)	2	2	
flu like symptoms			
alternative dictionary used: ctcae 4.03			
subjects affected / exposed	1 / 29 (3.45%)	0 / 55 (0.00%)	
occurrences (all)	1	0	
other-paraneoplastic fever			
alternative dictionary used: ctcae 4.03			

subjects affected / exposed	0 / 29 (0.00%)	1 / 55 (1.82%)	
occurrences (all)	0	1	
other-cold			
alternative dictionary used: ctcae 4.03			
subjects affected / exposed	1 / 29 (3.45%)	0 / 55 (0.00%)	
occurrences (all)	1	0	
Oedema mouth			
subjects affected / exposed	1 / 29 (3.45%)	0 / 55 (0.00%)	
occurrences (all)	1	0	
Inflammation	Additional description: inflammation of toe		
subjects affected / exposed	1 / 29 (3.45%)	0 / 55 (0.00%)	
occurrences (all)	1	0	
oedema limb			
alternative dictionary used: ctcae 4.03			
subjects affected / exposed	3 / 29 (10.34%)	3 / 55 (5.45%)	
occurrences (all)	3	3	
other-oedema head and neck			
alternative dictionary used: ctcae 4.03			
subjects affected / exposed	0 / 29 (0.00%)	1 / 55 (1.82%)	
occurrences (all)	0	1	
Immune system disorders			
allergic reaction			
alternative dictionary used: ctcae 4.03			
subjects affected / exposed	0 / 29 (0.00%)	2 / 55 (3.64%)	
occurrences (all)	0	2	
other-allergic in food factor			
alternative dictionary used: ctcae 4.03			
subjects affected / exposed	1 / 29 (3.45%)	0 / 55 (0.00%)	
occurrences (all)	1	0	
Reproductive system and breast disorders			
vagina pain			
alternative dictionary used: ctcae 3			
subjects affected / exposed	1 / 29 (3.45%)	0 / 55 (0.00%)	
occurrences (all)	1	0	
Respiratory, thoracic and mediastinal			

disorders			
Epistaxis			
subjects affected / exposed	4 / 29 (13.79%)	4 / 55 (7.27%)	
occurrences (all)	4	6	
other-pharynx pain			
alternative dictionary used: CTC AE 3			
subjects affected / exposed	0 / 29 (0.00%)	1 / 55 (1.82%)	
occurrences (all)	0	1	
Cough			
subjects affected / exposed	1 / 29 (3.45%)	2 / 55 (3.64%)	
occurrences (all)	2	2	
Dyspnoea			
subjects affected / exposed	2 / 29 (6.90%)	0 / 55 (0.00%)	
occurrences (all)	2	0	
Hiccups			
subjects affected / exposed	1 / 29 (3.45%)	0 / 55 (0.00%)	
occurrences (all)	1	0	
voice alteration			
alternative dictionary used: ctcae 4.03			
subjects affected / exposed	0 / 29 (0.00%)	1 / 55 (1.82%)	
occurrences (all)	0	1	
Pneumonitis			
subjects affected / exposed	1 / 29 (3.45%)	0 / 55 (0.00%)	
occurrences (all)	1	0	
Psychiatric disorders			
Insomnia			
subjects affected / exposed	1 / 29 (3.45%)	1 / 55 (1.82%)	
occurrences (all)	1	1	
Mood altered			
subjects affected / exposed	0 / 29 (0.00%)	5 / 55 (9.09%)	
occurrences (all)	0	5	
Hallucination	Additional description: occasionally		
subjects affected / exposed	0 / 29 (0.00%)	1 / 55 (1.82%)	
occurrences (all)	0	1	
Investigations			

White blood cell count decreased subjects affected / exposed occurrences (all)	25 / 29 (86.21%) 98	36 / 55 (65.45%) 130	
Lymphocyte count decreased subjects affected / exposed occurrences (all)	1 / 29 (3.45%) 5	2 / 55 (3.64%) 2	
Neutrophil count decreased subjects affected / exposed occurrences (all)	23 / 29 (79.31%) 77	33 / 55 (60.00%) 120	
Platelet count decreased subjects affected / exposed occurrences (all)	16 / 29 (55.17%) 47	32 / 55 (58.18%) 74	
Weight decreased subjects affected / exposed occurrences (all)	3 / 29 (10.34%) 3	1 / 55 (1.82%) 1	
Alanine aminotransferase increased subjects affected / exposed occurrences (all)	23 / 29 (79.31%) 57	31 / 55 (56.36%) 52	
Aspartate aminotransferase increased subjects affected / exposed occurrences (all)	19 / 29 (65.52%) 55	29 / 55 (52.73%) 56	
Alkaline Phosphatase Increased alternative dictionary used: CTCAE 4.03 subjects affected / exposed occurrences (all)	Additional description: ALP serum increased		
	8 / 29 (27.59%) 11	19 / 55 (34.55%) 23	
Blood bilirubin increased subjects affected / exposed occurrences (all)	4 / 29 (13.79%) 8	14 / 55 (25.45%) 18	
Hypercholesterolaemia subjects affected / exposed occurrences (all)	3 / 29 (10.34%) 3	4 / 55 (7.27%) 4	
creatinine increased alternative dictionary used: CTCAE 4.03 subjects affected / exposed occurrences (all)	Additional description: serum creatinine increased		
	4 / 29 (13.79%) 5	4 / 55 (7.27%) 7	

Gamma-glutamyltransferase increased subjects affected / exposed occurrences (all)	14 / 29 (48.28%) 14	25 / 55 (45.45%) 27	
Injury, poisoning and procedural complications Vascular access complication subjects affected / exposed occurrences (all)	1 / 29 (3.45%) 1	2 / 55 (3.64%) 2	
Cardiac disorders Tachycardia subjects affected / exposed occurrences (all)  Palpitations subjects affected / exposed occurrences (all)  Hypertension subjects affected / exposed occurrences (all)  Atrial fibrillation subjects affected / exposed occurrences (all)	1 / 29 (3.45%) 1  0 / 29 (0.00%) 0  0 / 29 (0.00%) 0  0 / 29 (0.00%) 0	0 / 55 (0.00%) 0  1 / 55 (1.82%) 1  1 / 55 (1.82%) 1  1 / 55 (1.82%) 1	
Nervous system disorders Dysgeusia subjects affected / exposed occurrences (all)  Nightmare subjects affected / exposed occurrences (all)  Dizziness subjects affected / exposed occurrences (all)  Somnolence subjects affected / exposed occurrences (all)  Neuropathy peripheral subjects affected / exposed occurrences (all)	1 / 29 (3.45%) 1  0 / 29 (0.00%) 0  1 / 29 (3.45%) 3  1 / 29 (3.45%) 1  0 / 29 (0.00%) 0	1 / 55 (1.82%) 1  1 / 55 (1.82%) 1  0 / 55 (0.00%) 0  0 / 55 (0.00%) 0  1 / 55 (1.82%) 1	

Tremor subjects affected / exposed occurrences (all)	1 / 29 (3.45%) 1	0 / 55 (0.00%) 0	
Headache subjects affected / exposed occurrences (all)	4 / 29 (13.79%) 4	0 / 55 (0.00%) 0	
Blood and lymphatic system disorders Anaemia subjects affected / exposed occurrences (all)	17 / 29 (58.62%) 30	33 / 55 (60.00%) 52	
Eye disorders Vision blurred subjects affected / exposed occurrences (all)	0 / 29 (0.00%) 0	1 / 55 (1.82%) 1	
Gastrointestinal disorders Constipation subjects affected / exposed occurrences (all)	3 / 29 (10.34%) 3	7 / 55 (12.73%) 9	
Diarrhoea subjects affected / exposed occurrences (all)	6 / 29 (20.69%) 7	13 / 55 (23.64%) 16	
Dry mouth subjects affected / exposed occurrences (all)	1 / 29 (3.45%) 1	0 / 55 (0.00%) 0	
Cheilitis subjects affected / exposed occurrences (all)	0 / 29 (0.00%) 0	2 / 55 (3.64%) 2	
Dyspepsia subjects affected / exposed occurrences (all)	1 / 29 (3.45%) 1	2 / 55 (3.64%) 2	
Stomatitis subjects affected / exposed occurrences (all)	5 / 29 (17.24%) 5	12 / 55 (21.82%) 14	
Nausea subjects affected / exposed occurrences (all)	7 / 29 (24.14%) 12	9 / 55 (16.36%) 12	
Vomiting			

subjects affected / exposed	4 / 29 (13.79%)	7 / 55 (12.73%)	
occurrences (all)	9	11	
Abdominal pain			
subjects affected / exposed	12 / 29 (41.38%)	10 / 55 (18.18%)	
occurrences (all)	26	16	
Haemorrhoids			
subjects affected / exposed	4 / 29 (13.79%)	0 / 55 (0.00%)	
occurrences (all)	4	0	
Dysphagia			
subjects affected / exposed	0 / 29 (0.00%)	1 / 55 (1.82%)	
occurrences (all)	0	1	
Flatulence			
subjects affected / exposed	0 / 29 (0.00%)	2 / 55 (3.64%)	
occurrences (all)	0	2	
Haemorrhage	Additional description: lower GI NOS		
subjects affected / exposed	0 / 29 (0.00%)	1 / 55 (1.82%)	
occurrences (all)	0	1	
Skin and subcutaneous tissue disorders			
Hyperhidrosis			
subjects affected / exposed	1 / 29 (3.45%)	0 / 55 (0.00%)	
occurrences (all)	4	0	
Rash			
subjects affected / exposed	8 / 29 (27.59%)	13 / 55 (23.64%)	
occurrences (all)	11	16	
Pruritus			
subjects affected / exposed	2 / 29 (6.90%)	2 / 55 (3.64%)	
occurrences (all)	2	2	
nail changes			
alternative dictionary used: ctcae 3			
subjects affected / exposed	0 / 29 (0.00%)	1 / 55 (1.82%)	
occurrences (all)	0	1	
Renal and urinary disorders			
urinary frequency			
alternative dictionary used: ctcae 4.03			
subjects affected / exposed	1 / 29 (3.45%)	1 / 55 (1.82%)	
occurrences (all)	1	1	

Urinary retention subjects affected / exposed occurrences (all)	0 / 29 (0.00%) 0	2 / 55 (3.64%) 2	
Haematuria subjects affected / exposed occurrences (all)	0 / 29 (0.00%) 0	1 / 55 (1.82%) 1	Additional description: microscopic
Endocrine disorders Glucose tolerance impaired subjects affected / exposed occurrences (all)	0 / 29 (0.00%) 0	4 / 55 (7.27%) 1	
Musculoskeletal and connective tissue disorders muscle weakness alternative dictionary used: ctcae 4.03 subjects affected / exposed occurrences (all)  Musculoskeletal pain subjects affected / exposed occurrences (all)	0 / 29 (0.00%) 0  5 / 29 (17.24%) 9	1 / 55 (1.82%) 1  5 / 55 (9.09%) 5	
Infections and infestations other-dermatology herpes alternative dictionary used: ctcae 3 subjects affected / exposed occurrences (all)  Catheter site infection subjects affected / exposed occurrences (all)  Urinary tract infection subjects affected / exposed occurrences (all)  Viral infection subjects affected / exposed occurrences (all)  Fungal infection subjects affected / exposed occurrences (all)  Upper respiratory tract infection	0 / 29 (0.00%) 0  1 / 29 (3.45%) 1  1 / 29 (3.45%) 1  2 / 29 (6.90%) 2  3 / 29 (10.34%) 1	2 / 55 (3.64%) 2  0 / 55 (0.00%) 0  4 / 55 (7.27%) 4  0 / 55 (0.00%) 0  0 / 55 (0.00%) 0	

subjects affected / exposed	1 / 29 (3.45%)	2 / 55 (3.64%)	
occurrences (all)	1	2	
Nail infection			
subjects affected / exposed	0 / 29 (0.00%)	1 / 55 (1.82%)	
occurrences (all)	0	1	
other-herpetic mucositis			
alternative dictionary used: ctcae 3			
subjects affected / exposed	0 / 29 (0.00%)	1 / 55 (1.82%)	
occurrences (all)	0	2	
Candida infection			
subjects affected / exposed	0 / 29 (0.00%)	1 / 55 (1.82%)	
occurrences (all)	0	1	
Metabolism and nutrition disorders			
anorexia			
subjects affected / exposed	13 / 29 (44.83%)	11 / 55 (20.00%)	
occurrences (all)	17	11	
Hyperglycaemia			
subjects affected / exposed	18 / 29 (62.07%)	21 / 55 (38.18%)	
occurrences (all)	46	34	
Hyperkalaemia			
subjects affected / exposed	6 / 29 (20.69%)	4 / 55 (7.27%)	
occurrences (all)	11	5	
Hypermagnesaemia			
subjects affected / exposed	0 / 29 (0.00%)	1 / 55 (1.82%)	
occurrences (all)	0	1	
Hypernatraemia			
subjects affected / exposed	1 / 29 (3.45%)	3 / 55 (5.45%)	
occurrences (all)	1	6	
Hypertriglyceridaemia			
subjects affected / exposed	4 / 29 (13.79%)	6 / 55 (10.91%)	
occurrences (all)	4	8	
Hyperuricaemia			
subjects affected / exposed	1 / 29 (3.45%)	3 / 55 (5.45%)	
occurrences (all)	1	6	
Hypoalbuminaemia			

subjects affected / exposed	14 / 29 (48.28%)	13 / 55 (23.64%)
occurrences (all)	22	20
Hypocalcaemia		
subjects affected / exposed	5 / 29 (17.24%)	13 / 55 (23.64%)
occurrences (all)	7	21
Hypoglycaemia		
subjects affected / exposed	1 / 29 (3.45%)	2 / 55 (3.64%)
occurrences (all)	1	2
Hypokalaemia		
subjects affected / exposed	8 / 29 (27.59%)	7 / 55 (12.73%)
occurrences (all)	16	11
Hyponatraemia		
subjects affected / exposed	7 / 29 (24.14%)	15 / 55 (27.27%)
occurrences (all)	15	28
Hypomagnesaemia		
subjects affected / exposed	0 / 29 (0.00%)	1 / 55 (1.82%)
occurrences (all)	0	1
Hypophosphataemia		
subjects affected / exposed	1 / 29 (3.45%)	2 / 55 (3.64%)
occurrences (all)	1	2
other-LDH		
alternative dictionary used: ctcae 4.03		
subjects affected / exposed	4 / 29 (13.79%)	1 / 55 (1.82%)
occurrences (all)	10	1

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
11 May 2012	changes in reporting requirements of serious adverse events

Notes:

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported